POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK

QR Code

POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK

Current possibilities of AT1 receptor blockers (ARBs), such as candesartan, for optimization of antihypertensive therapy in stroke patients are presented in the article. ARBs are original drugs that effect to the delicate balance of pressor and depressor neurohormonal systems. They also have cerebro...

Full description

Saved in:

Bibliographic Details
Main Author:	Z M. Sizova
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	hypertension stroke cerebroprotective effect angiotensin receptor blocker candesartan
Online Access:	https://www.rpcardio.online/jour/article/view/292
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Clinical pharmacogenetics of angiotensin II receptor blockers: new perspectives of pharmacotherapy individualization
by: D. A. Sychev, et al.
Published: (2006-04-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Arterial hypertension and Type 2 diabetes mellitus: any benefits for angiotensin II receptor blockers?
by: V. V. Fomin, et al.
Published: (2007-06-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2012-09-01)

BLOOD PRESSURE-LOWERING EFFICACY OF OLMESARTAN RELATIVE TO OTHER ANGIOTENSIN II RECEPTOR ANTAGONISTS: AN OVERVIEW OF RANDOMIZED CONTROLLED STUDIES
by: Faiez Zannad, et al.
Published: (2010-08-01)

INHIBITION OF KIDNEY DISORDERS IN CARDIOVASCULAR DISEASES: THE ROLE OF ANGIOTENSIN II RECEPTOR BLOCKERS
by: V. V. Fomin
Published: (2016-01-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

Angiotensin Receptor Blockade Does Not Decrease Synthetic Angiotensin II (Giapreza<sup>®</sup>) Effectiveness in Perioperative Hypotension Surrounding Kidney Transplant
by: Natalie Pettit, et al.
Published: (2025-06-01)

Left ventricular hypertrophy: renin4angiotensin system role
by: F. T. Ageev, et al.
Published: (2008-04-01)

The effect of the <i>M235T</i> polymorphism of the angiotensinogen gene on the office blood pressure during therapy with angiotensin II receptor blockers
by: E. V. Rebrova, et al.
Published: (2024-12-01)

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
by: A. S. Ryazanov, et al.
Published: (2023-01-01)

APPROACHES TO SELECTION OF ANTIHYPERTENSION DRUG WITHIN APPLIED LOWER TARGET BLOOD PRESSURE LEVELS
by: S. R. Gilyarevsky, et al.
Published: (2017-12-01)

Effect of insertion/deletion polymorphism of angiotensin-converting enzyme gene on efficacy of antihypertensive therapy with angiotensin II receptor blockers
by: E. V. Rebrova, et al.
Published: (2024-01-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

The role of angiotensin II type 1 receptor pathway in cerebral ischemia‒reperfusion injury: Implications for the neuroprotective effect of ARBs
by: Shuhan Huang, et al.
Published: (2024-06-01)

Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction
by: Harry Ridgway, et al.
Published: (2025-06-01)

PATIENTS WITH COMBINATION OF CHRONIC HEART FAILURE, HYPERTENSION AND HISTORY OF MYOCARDIAL INFARCTION: CLINICAL AND ANAMNESTIC CHARACTERISTICS, ADMINISTRATION OF ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, -BLOCKERS AND ADHERENCE TO THE DRUG THERAPY (DATA OF OUTPATIENT REGISTRY RECVASA)
by: M. M. Loukianov, et al.
Published: (2017-05-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

EFFECT OF ANGIOTENSIN-II RECEPTOR ANTAGONIST LOSARTAN AND ITS COMBINATION WITH DIURETICS ON MYOCARDIAL MORPHO-FUNCTIONAL CONDITIONS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY
by: S. N. Tolpygina, et al.
Published: (2016-01-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

Left ventricular hypertrophy: prognostic value, pathogenesis, possible remodeling: focusing on angiotensin receptor antagonists
by: M. D. Smirnova, et al.
Published: (2007-12-01)

Effect of Medical Therapy on Reducing the Risk of Pacing‐Induced Cardiomyopathy
by: Mahdi S. Agha, et al.
Published: (2025-07-01)

ANGIOTENSIN II RECEPTOR TYPE 1 EXPRESSION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS
by: I. S. Mykhailichenko
Published: (2016-04-01)

Use of angiotensin receptor blockers in cardiovascular protection. Current evidence and future directions
by: M. A. Munger
Published: (1970-01-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
by: M. L. Maksimov, et al.
Published: (2010-04-01)

PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY
by: S. A. Boytsov, et al.
Published: (2016-01-01)

The effect of renin-angiotensin system blockers on aldosterone levels in patients with chronic heart failure with preserved ejection fraction
by: A. N. Shevelok
Published: (2020-12-01)

Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19
by: O. M. Drapkina, et al.
Published: (2020-07-01)

HYPERTENSION IN POSTMENOPAUSAL WOMEN: RATIONALE FOR THE USE OF CALCIUM CHANNEL BLOCKERS IN ANTIHYPERTENSIVE THERAPY
by: O. A. Kislyak, et al.
Published: (2017-07-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

Candesartan effectiveness in essential arterial hypertension and renal arterial hypertension
by: N. M. Chikhladze, et al.
Published: (2008-12-01)